News | October 30, 2024
GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Strategic focus on COCO-model with a nationwide reach of 501 stores
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Konieczny has served as Interim CEO since April 2024
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
This project is supported by the Irish Government through IDA Ireland
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Subscribe To Our Newsletter & Stay Updated
